#UK #Antibody Market #CiteAb #RUO Antibodies #Bath

CiteAb Unveils Top 100 Cited RUO Antibodies

CiteAb, a prominent data analytics company focusing on the life sciences, recently published its latest findings in the annual Top 100 Cited Antibodies dataset. This comprehensive list, compiled using advanced AI-driven text-mining techniques, highlights the most frequently referenced antibodies in peer-reviewed research publications.

In a competitive market saturated with over eight million research-use-only (RUO) antibodies, these insights provide clarity on which suppliers and products are at the forefront of scientific innovation. The 2025 dataset indicates a continued strong performance from leading suppliers such as Cell Signaling Technology, Abcam, a Danaher company, and Thermo Fisher Scientific, with these three companies collectively dominating over two-thirds of the top 100 antibodies.

Key Trends in Antibody Usage

The latest data reveals several notable trends within the antibody landscape:

• - Recombinant Monoclonal Antibodies: About 25% of the top 100 are recombinant monoclonal antibodies, indicating significant interest in sustainable and renewable antibody solutions.
• - Secondary Antibodies on the Rise: There has been a noteworthy increase in the prominence of secondary antibodies, comprising 38% of the list—underscoring their essential role in various research applications.
• - Conjugated Antibodies: Antibodies tagged with conjugates like Alexa Fluor and IRDye are gaining traction, reflecting the ongoing demand for imaging applications in biological research.
• - Emerging Players: Companies like ABclonal and Proteintech are emerging as significant contributors, with Proteintech’s GAPDH antibody making it into the top 10.

Insights from CiteAb’s CEO

CiteAb's CEO, Dr. Andrew Chalmers, emphasizes the importance of this dataset, stating, "RUO antibodies play a critical role in research, and this data provides a valuable snapshot of what scientists are actually using. The top 100 list offers insight not only into vendor performance but also into where the research community is heading."

This annual survey not only reflects the competitive dynamics of the antibody market but also aids researchers, suppliers, and investors in understanding both current usage patterns and emerging trends.

CiteAb's dataset further signifies a shifting landscape where the research community's choices may influence future product developments and branding within the life sciences sector. The comprehensive dataset is available for free download and includes critical information such as company names, product types, and rankings.

Looking Ahead

CiteAb has plans to expand its Top 100 series later this year, with future datasets covering cell lines and bioactive small molecules, indicating the company's commitment to providing data-driven insights that foster innovation across various fields of life science research.

The research community, which extensively relies on this extensive dataset, can access the full findings and monitor future updates through CiteAb’s official platform. As scientists continue to navigate the challenges of biotechnological advancements, tools like this dataset will remain crucial in identifying effective reagents that drive forward scientific discovery.

For more detailed insights, you can visit CiteAb’s Official Blog.